Palatin Technologies Strengthens Intellectual Property with U.S. Patent for Vyleesi Drug.

Trending News ☀️

Palatin Technologies ($NYSEAM:PTN) has recently received an exciting and important victory from the United States Patent and Trademark Office (USPTO). The USPTO has granted Palatin Technologies a patent that strengthens the protection of its drug, Vyleesi, regarding its intellectual property. This is a major development for Palatin Technologies, as Vyleesi is the first and only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. This patent not only adds to Palatin Technologies portfolio of intellectual property in the United States, but also around the globe.

The patent further strengthens Palatin Technologies’ position as a global leader in the development of drugs that treat HSDD. This patent gives Palatin Technologies the exclusive right to market Vyleesi and prevents any third parties from creating a generic or copycat drug. With the portfolio of intellectual property strengthened by this patent, Palatin Technologies can continue to lead the way in providing superior treatments to women suffering from HSDD.

Share Price

Palatin Technologies, a biopharmaceutical company, made headlines on Tuesday with the announcement that they had received a U.S. patent for their Vyleesi drug. This caused their stock to soar by 18.5%, from a prior closing price of $2.7 to an opening price of $2.9 and closing price of $3.2. The drug, Vyleesi, is used to treat premenopausal women with hypoactive sexual desire disorder, or HSDD. With the patent in place, the company can now move ahead with the marketing and selling of the drug. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Palatin Technologies. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Palatin Technologies. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Palatin Technologies. More…

Key Ratios Snapshot

Some of the financial key ratios for Palatin Technologies are shown below. More…

Analysis

At GoodWhale, we took a look at PALATIN TECHNOLOGIES‘ financials and conducted a risk analysis. We have determined that PALATIN TECHNOLOGIES is a high risk investment when it comes to both financial and business aspects. Therefore, we urge potential investors to do their own due diligence before investing. Upon deeper inspection, we have detected two risk warnings in the company’s income statement and balance sheet. For more detailed information regarding the risk warnings, we suggest that potential investors register on goodwhale.com. Once registered, they can access our comprehensive risk analysis and get the full picture of PALATIN TECHNOLOGIES’ financial status. More…

Peers

The company’s products are based on its proprietary technology platforms, which enable the targeted delivery of biologic and small molecule drugs. Palatin’s lead product candidates are VEN307, a topical gel for the treatment of acne vulgaris, and Rekkerd, a next-generation oral direct thrombin inhibitor. Palatin is also developing a portfolio of other product candidates for the treatment of various indications, including psoriasis, rosacea, and erectile dysfunction. The company’s competitors include OncoSec Medical Inc, Ember Therapeutics Inc, and Vaxxinity Inc.

– OncoSec Medical Inc ($NASDAQ:ONCS)

OncoSec Medical Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of novel cancer therapeutics. The company’s product candidates include TAVO, a T-cell therapy for the treatment of solid tumors, and KEYTRUDA, an anti-PD-1 antibody for the treatment of melanoma. OncoSec Medical Inc has a market cap of 7.52M as of 2022, a Return on Equity of -234.25%. The company’s product candidates are currently in clinical trials and have not yet been approved for commercial use.

– Ember Therapeutics Inc ($OTCPK:EMBT)

Ember Therapeutics Inc is a clinical stage biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat metabolic diseases. The company’s lead drug candidate is EBT-101, a first-in-class, orally available small molecule that is in development for the treatment of non-alcoholic steatohepatitis (NASH). Ember Therapeutics Inc has a market cap of 926.88k as of 2022 and a Return on Equity of 3.46%. The company’s focus on the discovery, development, and commercialization of small molecule drugs to treat metabolic diseases makes it a promising player in the healthcare industry.

– Vaxxinity Inc ($NASDAQ:VAXX)

Vaxxinity Inc is a clinical-stage biotechnology company focused on the development and commercialization of next-generation vaccines. The company has a market cap of 205.47M as of 2022 and a return on equity of -67.46%. The company’s lead product candidate is a novel vaccine platform called PENNVAX, which is based on a proprietary chimeric virus technology. PENNVAX is currently in clinical trials for the prevention of influenza and other infectious diseases.

Summary

Palatin Technologies recently announced the award of a U.S. patent for their Vyleesi drug, strengthening their intellectual property rights and adding to their competitive advantage. Investors responded quickly, with Palatin’s stock price moving up the same day. With this new protection, Palatin appears to be well-positioned to capitalize on increased demand in the marketplace, representing an attractive opportunity for long-term investors. This is especially true given its already solid financials and consistent dividend payments.

Furthermore, Palatin has been aggressive in expanding its research and development activities, investing in new products, and building relationships with key strategic partners. All these factors point to strong potential growth and increased shareholder value.